Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesRanjana H. Advani, Nathan Fowler, Joseph J. Buggy et al.|Journal of Clinical Oncology|2012Cited by 1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaRanjana H. Advani, Sonali M. Smith|New England Journal of Medicine|2018Cited by 1.1k
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, Deepa Jagadeesh et al.|Annals of Oncology|2014Cited by 138
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Tara Graff et al.|Blood|2024Cited by 132
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S. Ujjani, Bruce D. Cheson, Sin‐Ho Jung et al.|Blood|2016Cited by 59